60 Degrees Pharmaceuticals (SXTP) Interest Expenses (2022 - 2026)
60 Degrees Pharmaceuticals (SXTP) posted quarterly Interest Expenses of $7400.0 for Q1 2026, down 79.69% year-over-year from $36427.0 in Q1 2025, and up 82.58% quarter-over-quarter from $4053.0 in Q4 2025.
60 Degrees Pharmaceuticals (SXTP) Interest Expenses (2022 - 2026) Analysis & Trends
60 Degrees Pharmaceuticals (SXTP) has reported Interest Expenses for 5 consecutive years, with $7400.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Expenses fell 79.69% year-over-year to $7400.0; the TTM figure through Mar 2026 stood at $7400.0 (down 79.69% YoY), while the FY2025 annual figure was $8.2 million, up 37.8% from the prior year.
- Interest Expenses climbed to $7400.0 in Q1 2026 per SXTP's latest filing, from $4053.0 in the prior quarter.
- Across five years, Interest Expenses topped out at $1.2 million in Q3 2022 and bottomed at -$83049.0 in Q4 2022.
- Historically, Interest Expenses has averaged $168879.8 across 5 years, with a median of $28401.0 in 2022.
- Annual changes were most pronounced in 2023 — Interest Expenses sank 99.59% — and 2025, when it surged 448.29%.
- 60 Degrees Pharmaceuticals' Interest Expenses stood at -$83049.0 in 2022, then surged by 105.95% to $4944.0 in 2023, then sank by 53.84% to $2282.0 in 2024, then surged by 77.61% to $4053.0 in 2025, then jumped by 82.58% to $7400.0 in 2026.
- Business Quant data shows SXTP's Interest Expenses at $7400.0 in Q1 2026, $4053.0 in Q4 2025, and $38435.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | 60 Degrees Pharmaceuticals | 3.00 Mn | 1.98 Mn | 56,798.00 | 1,403.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7,400.00 |
| Mar 31, 2026 | 7,400.00 |
| Dec 31, 2025 | 4,053.00 |
| Dec 31, 2025 | 4,053.00 |
| Sep 30, 2025 | 38,435.00 |
| Sep 30, 2025 | 38,435.00 |
| Jun 30, 2025 | 36,427.00 |
| Jun 30, 2025 | 36,427.00 |
| Mar 31, 2025 | 36,427.00 |
| Mar 31, 2025 | 36,427.00 |
| Dec 31, 2024 | 2,282.00 |
| Dec 31, 2024 | 2,282.00 |
| Sep 30, 2024 | 7,010.00 |
| Sep 30, 2024 | 7,010.00 |
| Jun 30, 2024 | 6,829.00 |
| Jun 30, 2024 | 6,829.00 |
| Mar 31, 2024 | 55,279.00 |
| Mar 31, 2024 | 55,279.00 |
| Sep 30, 2023 | 4,944.00 |
| Sep 30, 2023 | 4,944.00 |